CRICKi004-A

iFCI008

General

Cell Line

hPSCreg name CRICKi004-A
Cite as:
CRICKi004-A (RRID:CVCL_C3QZ)
Alternative name(s)
iFCI008
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
AIBNi015-A
(SPG1-AU01C15)
Donor diseases:
hereditary spastic paraplegia 56
RMCGENi020-A
(IPS15-00004)
Donor diseases:
Stargardt Disease
RMCGENi021-A
(IPS22-00087)
Donor diseases:
Stargardt Disease
SCTCi017-A
(IPS15-00006)
Donor diseases:
Stargardt disease
SCTCi018-A
(IPS15-00007)
Donor diseases:
Stargardt disease
ZZUi017-A
(ZZU-iPS-SCA6-001)
Donor diseases:
Spinocerebellar Ataxia Type 6
FRIMOi003-A
(STGD1_ FiPS4F1.5)
Donor diseases:
Stargardt Disease
LUMCi022-A
(115-1, LUMC0115iATAX01)
Donor diseases:
Spinocerebellar Ataxia Type 1
LUMCi022-B
(115-2, LUMC0115iATAX02)
Donor diseases:
Spinocerebellar Ataxia Type 1
LUMCi022-C
(115-7, LUMC0115iATAX07)
Donor diseases:
Spinocerebellar Ataxia Type 1
SAPi002-A
(ALS I, ALS I–FUS-R514S/wt, FUS-R514S/wt)
Donor diseases:
amyotrophic lateral sclerosis
ZZUi024-A
(ZZU-iPS-AD-APP-002)
Donor diseases:
Alzheimer's Disease
LCPHi001-A
Donor's gene variants:
GBA
Donor diseases:
obsolete_Parkinson's disease
UKBi014-A
(A-257s2)
Donor diseases:
Walker-Warburg syndrome
DANi004-A
(PRKN-004-C1)
Donor's gene variants:
PRKN
Donor diseases:
Parkinson's Disease
DANi006-F
(GBA-006-C6)
Donor's gene variants:
GBA
Donor diseases:
Parkinson's Disease
DANi011-A
(LRRK2-011-C1)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson's Disease
LCSBi009-A
(RHOT1_R272Q_clone1_PD)
Donor diseases:
Parkinson's Disease
LCSBi010-A
(RHOT1_R450C_clone5_PD)
Donor diseases:
Parkinson's Disease
UCSCi001-A
(SII-1802)
Donor diseases:
Amyotrophic Lateral Sclerosis
LUMCi002-A
(113-6, LUMC0113iATAX06)
Donor diseases:
Spinocerebellar Ataxia Type 1
ZZUi030-A
(ZZU-iPS-SPG7-001)
Donor diseases:
Spastic paraplegia type 7
LUMCi002-B
(113-7, LUMC0113iATAX07)
Donor diseases:
Spinocerebellar Ataxia Type 1
LUMCi002-C
(113-8, LUMC0113iATAX08)
Donor diseases:
Spinocerebellar Ataxia Type 1
CRICKi005-A
(iFCI004)
Donor diseases:
spinal muscular atrophy
CRICKi006-A
(iFCI005)
Donor diseases:
spinal muscular atrophy
HDZi003-A
(hiPSC NP0038)
Donor's gene variants:
TMEM43
Donor diseases:
arrhythmogenic right ventricular dysplasia 5
FRIMOi004-A
(STGD2_ FiPS4F1.7)
Donor diseases:
Stargardt Disease
HIHDNDi001-A
(A30P-3, SNCA3, Tue_020_A)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
autosomal dominant Parkinson disease 1
HIHDNDi001-B
(A30P-4, SNCA4, Tue_020_B)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
autosomal dominant Parkinson disease 1
ZZUi026-A
(ZZU-iPS-SCA3-003)
Donor diseases:
Spinocerebellar Ataxia Type 3
Last update 12th December 2022
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator The Francis Crick Institute Limited (CRICK)
Owner The Francis Crick Institute Limited (CRICK)
Distributors

External Databases

BioSamples SAMEA111497816
Cellosaurus CVCL_C3QZ
Wikidata Q116048787

General Information

Publications
* Is the cell line readily obtainable for third parties?
No

Donor Information

General Donor Information

Sex female
Age of donor (at collection) 1-4
Ethnicity 3 years old

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • spinal muscular atrophy with lower extremity predominance
Disease associated phenotypes
  • Spinal muscular atrophy with lower extremity dominant (SMALED)

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
The KaryoStat™ assay allows for digital visualization of chromosome aberrations with a resolution similar to g-banding karyotyping by relying on 150k SNP probes across the human genome. The size of structural aberration that can be detected is > 2 Mb for chromosomal gains and > 1 Mb for chromosomal losses. The assay enables the detection of aneuploidies, submicroscopic aberrations, and mosaic events.
Karyotyping method: G-Banding

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA111509442

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? Yes
Contact information / weblink https://www.ucl.ac.uk/child-health/mrc-cnmd-biobank-london
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Unknown
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? No
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? No
How may genetic information associated with the cell line be accessed? Open Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? The London – West London & GTAC Research Ethics Committee (formerly known as the Hammersmith, Queen Charlotte's and Chelsea Research Ethics Committee).
Approval number 08ND17
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
Synonyms
  • fibroblast
  • Fibroblasts
  • Fibroblast
  • FIBROBLAST
show more synonyms
Age of donor (at collection) 1-4
Passage number reprogrammed 2

Reprogramming method

Vector type None

Vector free reprogramming

Type of used vector free reprogramming factor(s)
mRNA
mRNA

Other

Selection criteria for clones Manually picked
Derived under xeno-free conditions
Yes
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
O2 Concentration 5 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Morphology pictures
Flow Cytometry
Method documentation
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
In vitro directed differentiation
Scorecard
Morphology
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
In vitro directed differentiation
Scorecard
Morphology
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
In vitro directed differentiation
Scorecard
Morphology

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
The KaryoStat™ assay allows for digital visualization of chromosome aberrations with a resolution similar to g-banding karyotyping by relying on 150k SNP probes across the human genome. The size of structural aberration that can be detected is > 2 Mb for chromosomal gains and > 1 Mb for chromosomal losses. The assay enables the detection of aneuploidies, submicroscopic aberrations, and mosaic events.

Other Genotyping (Cell Line)